[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reflux-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reflux-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637418","early-phase-1-development-of-a-preparation-for-supportive-supplementation-of-probiotics-in-patients-with-reflux-100637418",false,"NCT07600008","Development of a Preparation for Supportive Supplementation of Probiotics in Patients With Reflux","Inclusion Criteria:\n\n* Diagnosed GERD.\n* Stable health without current complications.\n* Patients on stable pharmacological PPI therapy (rabeprazole).\n\nExclusion Criteria:\n\n* Use of probiotics or prebiotics within the last 4 weeks.\n* Pregnancy or breastfeeding.\n* Systemic antimicrobial therapy within the last 4 weeks.\n* Infectious disease of the respiratory or gastrointestinal tract within the last 2 weeks.\n* Serious chronic disease that could affect study results, including cancer, diabetes, inflammatory bowel disease, diagnosed SIBO.\n* Prior surgeries, especially fundoplication and resections of the esophagus or stomach.\n* Patients with psychiatric or cognitive disorders.\n* Hypersensitivity to components of the investigational product.","ALL","40 Years","55 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","A two-arm, double-blind, randomized, placebo-controlled study investigating the efficacy of a probiotic preparation developed as supportive supplementation of probiotics in patients with reflux.\n\nThe objective of this trial is to evaluate the effect of the probiotic dietary supplement on the diversity and composition of the gut microbiome in patients diagnosed with GERD who are on PPI therapy. The study will also monitor changes in the oral microbiome and the impact of probiotic supplementation on patient quality of life and GERD symptoms.\n\nPatients will take the probiotic preparation, 2 tablets twice daily (morning before meals and evening after meals). The experimental phase will last 6 weeks. Patients in the control arm will receive placebo. Supplementation will be discontinued if adverse effects occur.\n\nOral and rectal swabs will be taken before and after administration of the preparation. Patients will monitor their symptoms using a questionnaire.",[26,27,28],"Reflux Disease","Microbiome","Probiotics Supplement","RECRUITING","2026-05-17",{"date":32,"type":33},"2026-05-20","ACTUAL",{"date":35,"type":33},"2026-01-15",{"date":37,"type":20},"2026-07-30",{"name":39,"class":40},"University Hospital Olomouc","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100526033","deprescribing-inappropriate-proton-pump-inhibitors-100526033","NCT06129474","Deprescribing Inappropriate Proton Pump Inhibitors","DepRescribing inapprOpriate Proton Pump InhibiTors - the DROPIT Trial: a Cluster Randomized Controlled Trial in Primary Care Setting","DROPIT","Inclusion Criteria:\n\n1. Patient of a participating GP.\n2. Age: minimum 18 years old.\n3. Daily PPI intake for minimum 8 weeks.\n4. PPI in one of the following doses:\n\n   * minimum 40mg\u002Fday pantoprazole;\n   * minimum 40mg\u002Fday omeprazole;\n   * more than 30mg\u002Fday lansoprazole;\n   * more than 30mg\u002Fday dexlansoprazole;\n   * more than 20mg\u002Fday esomeprazole;\n   * more than 20mg\u002Fday rabeprazole.\n5. Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment.\n\nExclusion Criteria:\n\n1. Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.\n2. Unable to provide informed consent.\n3. PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:\n\n   * History of bleeding ulcer.\n   * Peptic ulcer due to cause other than NSAID or H. Pylori.\n   * Barrett's oesophagus.\n   * Severe erosive reflux disease (Los Angeles grade C\u002FD).\n   * GERD with symptoms or complications (oesophageal ulcer, peptic stricture).\n   * Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea refractory to enzyme replacement therapy, idiopathic pulmonary fibrosis.)\n4. Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below.\n\nMedications (any dose):\n\n* Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days.\n* Antiplatelet therapy.\n* Additional antiplatelet therapy (e.g., ticagrelor or similar).\n* Anticoagulant(s).\n* Systemic steroid(s) for more than 1 month.\n\nRisk factors:\n\n* History of gastrointestinal ulcer.\n* Age of 75 years and older.\n* Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use.\n* Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).","18 Years",{"count":52,"type":20},400,[54],"NA","The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.",[57,26,58],"Inappropriate Prescribing","Proton Pump Inhibitors",[60,61],"Deprescribing","Proton pump inhibitors","2026-05-11",{"date":64,"type":33},"2026-05-14",{"date":66,"type":33},"2024-10-01",{"date":68,"type":20},"2027-12-31",{"name":70,"class":40},"University of Bern"]